Heinz Lubenau

Company: NEC Bio Therapeutics

Job title: Chief Executive Officer

Seminars:

Advancing Personalized Cancer Vaccines Through AI-Driven Antigen Prediction & Clinical Translation 12:30 pm

• How NEC Bio’s AI models improve the precision and relevance of neoantigen prediction, driving stronger immune responses and measurable patient benefit • Integrating immunogenicity data and clinical outcomes to continuously refine AI models and improve predictive performance • Insights from NECVAX-NEO1, a bacteria-based oral PCV, in improving delivery, accessibility, and patient experience beyond injectable…Read more

day: Conference Day One